Skip to main content
721 search results for:

Neratinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | Neratinib | OriginalPaper

    NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

    In 2013, T-DM1 was the first HER2-targeted antibody–drug conjugate (ADC) granted FDA-approval for late-stage metastatic breast cancer after prior trastuzumab. In 2019, T-DM1 was approved as post-neoadjuvant therapy in patients with residual …

  2. 01-04-2022 | Breast Cancer | News

    Neratinib

    Acquired drug resistance leading to disease progression: 2 case reports
  3. Open Access 01-12-2021 | Breast Cancer | ReviewPaper

    How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer

    Over the last 20 years, treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer has considerably improved. The development and addition of (neo)adjuvant trastuzumab to chemotherapy in patients with …

  4. 01-08-2020 | Duodenal Ulcer | News

    Neratinib

    Mucositis and duodenal ulcer: case report
  5. Open Access 14-06-2023 | Neratinib | OriginalPaper

    A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

    The epidermal growth factor family of trans-membrane receptors (ERBB family) members are effective mediators of normal cell growth and development [ 1 ]. The ERBB family of transmembrane receptor tyrosine kinases (RTKs) is comprised of four closely …

  6. 01-10-2019 | Panniculitis | News

    Neratinib

    Facial swelling and foreign body granulomatous reaction: case report
  7. 17-08-2022 | Metastasis | OriginalPaper

    Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital

    Approximately, 15–20% of metastatic breast cancers (MBCs) are characterised by overexpression or amplification of human epidermal growth factor receptor 2 (HER2), a biomarker that was historically associated with aggressive disease and poor …

  8. Open Access 01-12-2019 | Fluorescence in Situ Hybridization | OriginalPaper

    PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

    Randomized phase III studies have demonstrated that 12 months’ treatment with the anti-HER2 antibody trastuzumab plus adjuvant chemotherapy significantly improves clinical outcomes in women with HER2-positive early-stage breast cancer (BC) [ 1 – 3 …

  9. Open Access 01-12-2019 | Metastasis | OriginalPaper

    Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis

    Breast cancer metastasis to distant organs such as the liver, lung, bone and brain is a leading cause of cancer-related mortality in women and is estimated to account for 626,679 deaths globally in 2018 [ 1 ]. Patients with the human epidermal …

  10. 04-11-2022 | Pharmacokinetics | OriginalPaper

    The influence of verapamil on the pharmacokinetics of the pan-HER tyrosine kinase inhibitor neratinib in rats: the role of P-glycoprotein-mediated efflux

    Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has been approved for the treatment of HER2-positive (HER2+) early-stage and brain metastatic breast cancer. Thus far, the pharmacology effects and pharmacodynamics of neratinib have …

  11. Open Access 01-12-2019 | Breast Cancer | OriginalPaper

    Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial

    Diarrhea is a well-recognized side effect of chemotherapeutic and targeted regimens used to treat breast cancer, including pertuzumab-based regimens [ 1 , 2 ], docetaxel plus capecitabine [ 3 ], and capecitabine plus lapatinib [ 4 ]. Despite the …

  12. Open Access 01-12-2019 | Breast Cancer | OriginalPaper

    NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

    Human epidermal growth factor receptor 2 (HER2/ ERBB2 ) is overexpressed in approximately 25% of breast cancers and drives hyperactivation of the HER2 pathway via downstream signaling initiated by receptor homo- or hetero-dimerization with other …

  13. Open Access 01-06-2022 | Breast Cancer | OriginalPaper

    Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature

    Breast cancers characterized by human epidermal growth factor receptor 2 (HER2) overexpression represent a common, aggressive subtype, comprising approximately 20% of breast cancers [ 1 ]. Although trastuzumab has improved outcomes for patients …

  14. 01-02-2019 | Breast Cancer | Erratum

    Correction to: Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU

    An Online First version of this article was made available online at.

  15. Open Access 01-06-2021 | Breast Cancer | OriginalPaper

    Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval

    Breast cancer is the most common cancer in women and approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2) [ 1 – 3 ]. HER2-positive breast cancer was historically associated with a worse prognosis; however …

  16. 01-01-2021 | Breast Cancer | OriginalPaper

    Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant

    Small molecule tyrosine kinase inhibitors (TKIs) are increasingly used for the treatment of cancers in blood and solid tissues. These drugs compete with the intracellular ATP binding site of oncogenic tyrosine kinases including the ErbB group [ 1 …

  17. Open Access 01-07-2021 | Constipation | OriginalPaper

    Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

    Overall survival in patients with human epidermal growth factor receptor (HER)2-positive metastatic breast cancer (MBC) has continued to improve over the past decade due to advancements in HER2-directed therapies [ 1 , 2 ], but it remains difficult …

  18. 01-07-2019 | Doxycycline | News

    Neratinib

    Paronychia, xerosis and acneiform rash : case report
  19. Open Access 01-10-2021 | Metastasis | OriginalPaper

    Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

    Breast cancer has been the most prevalent cancer and the leading cause of cancer death among women. The number of patients with newly diagnosed breast cancer has surged from 1.7 million in 2012 to over 2.1 million in 2018, according to the …

  20. 01-12-2020 | Breast Cancer

    Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

    After the publication of this work [1] the authors have reported that in Table 3 The letter “T” in columns 5 and 7 should not be there.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.